seen from Netherlands
seen from United States
seen from T1
seen from China
seen from Italy
seen from Türkiye
seen from Netherlands
seen from Macao SAR China
seen from United States
seen from Pakistan
seen from Malaysia
seen from Germany
seen from United States
seen from Canada
seen from United States
seen from Türkiye
seen from Pakistan
seen from T1
seen from Pakistan
seen from T1
Men living with HIV who are on antiretroviral (ARV) treatment experience faster decline in their kidney function compared with HIV-negative men, aidsmap reports.
Publishing their findings in the journal AIDS, researchers studied data from the Multicenter AIDS Cohort on 917 HIV-positive men on ARVs, 159 HIV-positive men not on ARVs and 1,305 HIV-negative men. The study period ran from October 2003 to September 2014.
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Among those starting HIV treatment for the first time, Edurant (rilpivirine) is superior to Sustiva (efavirenz) on multiple measures, aidsmap reports.
Publishing their findings in HIV Medicine, researchers conducted a multicenter, prospective and observational study of 1,490 people with HIV who started their first antiretroviral (ARV) treatment with Edurant (786 people) or Sustiva (704 people) and were members of the Italian Cohort Native Antiretrovirals Foundation Study. All participants began the study with a viral load below 100,000.
COMPLERA EMTRICITABINA / RILPIVIRINA / FUMARATO DE DISOPROXILO DE TENOFOVIR (Combinación farmacéutica) #complera #emtricitabina #rilpivirina #fumarato #disoproxilo #tenofovir #arv #retrovirrales #antiretrovirrales #salud #saludresponsable #saludybienestar #saludable #saludables #medic #medicine #medicinas #medicina #medicinaestética https://www.instagram.com/p/CBBckEtnoWu/?igshid=7ydg7zzdkvxb
Gilead Sciences, the pharmaceutical giant that has long dominated the HIV treatment market, owes its success to something of a wonder drug: tenofovir. The antiretroviral (ARV), which for nearly two decades has come in a form known as tenofovir disoproxil fumarate, or TDF, is highly effective and well tolerated. However, TDF is associated with kidney and bone toxicities. Seeking to rectify this downside, Gilead recently developed tenofovir alafenamide, or TAF, an updated version of TDF.
Hi doc Switched from atripla to complera 2 weeks back and suffering from bloating and night sweats(one of the reason for switch). I have tried everything.. I take my meds in night before bed. Is it usual to have such side effects with complera? How long should I wait to so see the ease?
It’s unusual–Complera is usually much better tolerated than Atripla–but there are exceptions to every rule.
Remember that for adequate absorption, Complera must be taken with a meal, so it’s unusual to take it at bedtime. Also, if you’re a man and you’re having nightsweats on both medications, you may have hypogonadism (low testosterone levels). Consider getting a morning free testosterone level drawn.
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Hello Dr Gallant. On a previous question you answered that treating H. pylori infection while on Odefsey is tricky. I asked about my HIV doctor and he said that the risk is theoretical since treatment is only for 10 days. On the leaflet of Odefsey states no co-administration with PPIs with no asterisks about short treatment period or taking the meds several hours apart. I want your opinion also since I am very reluctant to follow my doctor's view and start treatment for Hp while on Odefsey. Tx!
Your doctor is right that it’s theoretical in that it hasn’t been specifically reported, but it would still make me nervous. I would worry that going 10 consecutive days with subtherapeutic rilpivirine levels could be enough to result in viral rebound and resistance.
Hi Dr Joel, I am 39 Male living in UK. I have been on HIV medication Eviplera for last two year. My VL/CD4 are UD/670, no other health issue. I am tolerating well Eviplera and plsning to swith Odefsey as soon as available in UK. Understand from some your forum, complera has low barrier to resistance and resistance to complera will resistance entire NNRTI . Considering above point, a person in my situation should consider for change to new medicine like Genvoya, Triumeq or Trivcay?
If you don’t miss doses, don’t mind taking your meds with a meal, and have a consistently undetectable viral load, then you shouldn’t worry about the resistance barrier of either Eviplera (Complera in the U.S.) or Odefsey. The resistance barrier is more of a concern when we start people on treatment for the first time and we don’t know whether they’ll be good at taking medications.
Hi, Dr. Gallant! I've been on treatment since 2009 (atripla first, complera since last year). Since I became undetectable, I've had one blip (a 400 vl), and multiple vl just over the detection treshold (three 20's, a 50 and a 70). I'm completely adherent, though the rilpivirine meal requirement is sometimes difficult to meet. My doctor just switched me to triumeq because of the DTG resistance barrier, though she thinks the low level viremia has no significance. Do you agree with this switch?
You shouldn’t be on Complera if you have difficulty with the meal requirement. That may have nothing to do with your viral loads, but Triumeq is a more appropriate choice if you sometimes take your meds on an empty stomach.
